Overview

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Exper

Status:
Completed

Trial end date:
2012-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the pharmacokinetics (how the body absorbs, distributes, metabolizes and eliminates a drug) (PK) of ETR when given with ATV/rtv and 1 NRTI in treatment experienced HIV-1 infected patients. In addition, safety, tolerability and anti-HIV effect of this regimen will also be studied. A total of 46 patients will be enrolled.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen R&D Ireland

Treatments:

Atazanavir Sulfate
Etravirine
Reverse Transcriptase Inhibitors
Ritonavir
Tenofovir